{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-013889","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.810749+00:00","generated_at":"2026-05-30T08:27:52.857426+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dogwood Therapeutics regains Nasdaq compliance; phase 2a Long-COVID data expected mid-Nov","bullets":["Regained Nasdaq minimum bid price compliance; closing bid price >= $1.00 for 10 consecutive trading days.","Top-line results from phase 2a study of IMC-2 for Long-COVID expected mid-November 2024.","Integration of Pharmagesic (Holdings) Inc. acquisition (closed early Oct 2024) ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-013889","json":"https://secwatch.observer/filing/0001558370-24-013889.json","markdown":"https://secwatch.observer/filing/0001558370-24-013889.md","text":"https://secwatch.observer/filing/0001558370-24-013889.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000155837024013889/0001558370-24-013889-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000155837024013889/viri-20241029x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:27:52.857426+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}